Literature DB >> 12945056

Conformational interconversion in compstatin probed with molecular dynamics simulations.

Buddhadeb Mallik1, John D Lambris, Dimitrios Morikis.   

Abstract

Compstatin is a 13-residue cyclic peptide that has the potential to become a therapeutic agent against unregulated complement activation. In our effort to understand the structural and dynamic characteristics of compstatin that form the basis for rational and combinatorial optimization of structure and activity, we performed 1-ns molecular dynamics (MD) simulations. We used as input in the MD simulations the ensemble of 21 lowest energy NMR structures, the average minimized structure, and a global optimization structure. At the end of the MD simulations we identified five conformations, with populations ranging between 9% and 44%. These conformations are as follows: 1) coil with alphaR-alphaR beta-turn, as was the conformation of the initial ensemble of NMR structures; 2) beta-hairpin with epsilon-alphaR beta-turn; 3) beta-hairpin with alphaR-alphaR beta-turn; 4) beta-hairpin with alphaR-beta beta-turn; and 5) alpha-helical. Conformational switch was possible with small amplitude backbone motions of the order of 0.1-0.4 A and free energy barrier crossing of 2-11 kcal/mol. All of the 21 MD structures corresponding to the NMR ensemble possessed a beta-turn, with 14 structures retaining the alphaR-alphaR beta-turn type, but the average minimized structure and the global optimization structures were converted to alpha-helical conformations. Overall, the MD simulations have aided to gain insight into the conformational space sampled by compstatin and have provided a measure of conformational interconversion. The calculated conformers will be useful as structural and possibly dynamic templates for optimization in the design of compstatin using structure-activity relations (SAR) or dynamics-activity relations (DAR). Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12945056     DOI: 10.1002/prot.10491

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  9 in total

1.  New compstatin variants through two de novo protein design frameworks.

Authors:  M L Bellows; H K Fung; M S Taylor; C A Floudas; A López de Victoria; D Morikis
Journal:  Biophys J       Date:  2010-05-19       Impact factor: 4.033

2.  Kinetics and thermodynamics of type VIII beta-turn formation: a CD, NMR, and microsecond explicit molecular dynamics study of the GDNP tetrapeptide.

Authors:  Patrick F J Fuchs; Alexandre M J J Bonvin; Brigida Bochicchio; Antonietta Pepe; Alain J P Alix; Antonio M Tamburro
Journal:  Biophys J       Date:  2006-01-27       Impact factor: 4.033

Review 3.  Compstatin: a complement inhibitor on its way to clinical application.

Authors:  Daniel Ricklin; John D Lambris
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

4.  A new generation of potent complement inhibitors of the Compstatin family.

Authors:  Aliana López de Victoria; Ronald D Gorham; Meghan L Bellows-Peterson; Jun Ling; David D Lo; Christodoulos A Floudas; Dimitrios Morikis
Journal:  Chem Biol Drug Des       Date:  2011-04-26       Impact factor: 2.817

5.  Design of a modified mouse protein with ligand binding properties of its human analog by molecular dynamics simulations: the case of C3 inhibition by compstatin.

Authors:  Phanourios Tamamis; Panayiota Pierou; Chrystalla Mytidou; Christodoulos A Floudas; Dimitrios Morikis; Georgios Archontis
Journal:  Proteins       Date:  2011-08-30

6.  Novel compstatin family peptides inhibit complement activation by drusen-like deposits in human retinal pigmented epithelial cell cultures.

Authors:  Ronald D Gorham; David L Forest; Phanourios Tamamis; Aliana López de Victoria; Márta Kraszni; Chris A Kieslich; Christopher D Banna; Meghan L Bellows-Peterson; Cynthia K Larive; Christodoulos A Floudas; Georgios Archontis; Lincoln V Johnson; Dimitrios Morikis
Journal:  Exp Eye Res       Date:  2013-08-15       Impact factor: 3.467

7.  Species specificity of the complement inhibitor compstatin investigated by all-atom molecular dynamics simulations.

Authors:  Phanourios Tamamis; Dimitrios Morikis; Christodoulos A Floudas; Georgios Archontis
Journal:  Proteins       Date:  2010-09

8.  Molecular dynamics in drug design: new generations of compstatin analogs.

Authors:  Phanourios Tamamis; Aliana López de Victoria; Ronald D Gorham; Meghan L Bellows-Peterson; Panayiota Pierou; Christodoulos A Floudas; Dimitrios Morikis; Georgios Archontis
Journal:  Chem Biol Drug Des       Date:  2012-02-09       Impact factor: 2.817

9.  Novel analogues of the therapeutic complement inhibitor compstatin with significantly improved affinity and potency.

Authors:  Hongchang Qu; Paola Magotti; Daniel Ricklin; Emilia L Wu; Ioannis Kourtzelis; You-Qiang Wu; Yiannis N Kaznessis; John D Lambris
Journal:  Mol Immunol       Date:  2010-11-09       Impact factor: 4.407

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.